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Abstract
Behçet’s disease (BD) is a chronic refractory multi-system autoimmune disorder 
with a strong genetic component. Like many other human complex diseases, mul-
tiple genes with polymorphisms have been associated with BD. These genes encode 
proteins involved mainly in immune regulation and inflammation and some in 
transcriptional activation and post-translational modification. Understanding the 
genetic association of these genes with BD may provide insight into the pathogen-
esis and for development of new, targeted therapies for this human complex disease.
Keywords: Behçet’s disease, genetic, HLA region, interleukin family,  
inflammation and autoimmunity, transcriptional activation
1. Introduction
Behçet’s disease (BD) is a chronic inflammatory disorder with unclear etiology. It 
can affect a variety of organs characterized by refractory ulcers in genitals and mouth, 
uveitis, skin lesions, and manifestations in joints, gastrointestinal tract, kidneys, lungs, 
and cardiovascular and central nervous systems [1]. BD has distinctive geographical 
distribution, and it is found primarily in populations along the ancient Silk Route 
from the Mediterranean region transiting through Central Asia to East Asia [2]. The 
reported prevalence of BD varies between Western (0.12–7.5 per 100,000) [3] and 
Eastern countries (6.3–14 per 100,000) [4]. Turkey has the highest incidence of BD in 
general population (80–420 per 100,000) [5–7]. A family history of BD significantly 
increases the risk at a rate of 31.2% [8], which indicates a strong genetic contribution 
to the disease by comparing to general population. Men are more commonly affected 
in Middle Eastern countries, but that appears opposite in USA, Brazil, Israel, and Korea 
[9]. The first reported genetic association of BD was found in the human leukocyte 
antigen (HLA) region, or the major histocompatibility complex (MHC) on chromo-
some 6 [10]. HLA-B51 confers the strongest genetic risk to BD [11]. Multiple other 
genetic factors outside the HLA region have also been identified. The following are the 
categorized genes associated with BD reported from 1973 to January 2019.
2. HLA and HLA-related genes
2.1 HLA
HLA genes are among the most polymorphic genes in the human genome, and 
they are associated with almost all autoimmune diseases. HLA-B51 is the strongest 
risk allele for BD, which has been replicated in almost all studied populations [12–22]. 
The population attributable risk (PAR) of HLA-B5/B51 was estimated as 52.2% for BD 
Different Aspects of Behçet’s Disease
2
patients in Southern Europe, 49.9% in Middle East/North Africa, 44.4% in East Asia, 
and 31.7% in Northern Europe [23]. Other HLA alleles including BD-risk HLA-A02, 
-A24, -A26, -A31, -B27, -B57, and BD-protective HLA-A03, -B15, -B35, -B49, -B58 were 
reported in different populations [22, 24–29].
Certain HLA alleles were also associated with clinical outcomes of BD. BD 
patients carrying HLA-A26:01 have a poor visual prognosis in Japan [30] and a high 
incidence of posterior uveitis in Korea [31]. Some HLA alleles were associated with 
lesions of specific organs in the Korean and Japanese patients, such as HLA-A26:01 
with uveitis, HLA-A02:07 with skin lesions and arthritis, and -A30:04 with vascular 
lesions, genital ulcers, and a positive pathergy test [32]. These findings suggest that 
specific HLA alleles are likely used as genetic markers for subclassification and/or 
prognostic evaluation of BD patients.
2.2 CIITA
The class II major histocompatibility complex transactivator (CIITA) is a tran-
scriptional activator that acts as a master regulator of the HLA class II genes and 
some other immune-mediating genes [33, 34]. A single nucleotide polymorphism 
(SNP) of the CIITA gene rs12932187 with G allele and GG genotype appeared to be a 
risk factor to Chinese BD, and the GG carriers were correlated with a higher expres-
sion of the CIITA gene, and with a lower level of IL-10 protein from the peripheral 
blood mononuclear cells (PBMC) in response to lipopolysaccharide (LPS) [35].
2.3 ERAP1
Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an essential enzyme to 
trim peptides in the ER for optimized binding by MHC class I molecules. The asso-
ciation between ERAP1 and BD was first reported in a Turkish population and was 
replicated in a Chinese cohort, in which the SNPs rs10050860 and rs17482078 of the 
ERAP1 gene encoding variants of amino acids Asp575Asn and Arg725Gln, respec-
tively, conferred risk to BD [36, 37]. Further analysis of the association indicated 
that the ERAP1 variant Arg725Gln may interact with the HLA-B51 protein to confer 
susceptibility to BD [36, 38]. Moreover, the expression of ERAP1 was found to be 
significantly lower in active BD patients [37], and the patients carrying AA and 
CC genotype of the ERAP1 SNP rs1065407 and rs10050860, respectively, showed a 
higher expression level of the ERAP1 gene than the patients carrying AC or CC and 
CT or TT genotypes of the SNPs, respectively, in response to LPS [37, 38].
2.4 MICA
The major histocompatibility complex class I chain-related gene A (MICA), 
located on the centromeric side of the HLA-B gene on chromosome 6, is highly 
polymorphic [39]. It functions in immune activation under cellular stress condi-
tions, such as infections, tissue injury, pro-inflammatory signals, and malignant 
transformation [40]. There have been more than 100 MICA alleles identified 
according to its overall sequence variations. In addition, the codon 295 of the MICA 
gene has a tri-nucleotide microsatellite polymorphism (GCT)n that is designated as 
An (A4, A5, A6, A9) allele, and a five repetition of GCT may coexist with a guano-
sine insertion that is designated as A5.1 [41].
MICA*009 and *019 alleles were associated with BD in a Spanish population 
[42], and MICA-A6 allele with Japanese and Korean BD patients [43–45]. The latter 
appeared to be independent from the potential linkage disequilibrium (LD) effect 
of HLA-B51 according to the Korean study [45].
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On the other hand, MICA-A5.1 demonstrated a negative correlation with ocular 
lesions and iridocyclitis in BD patients [45, 46]. MICA-A9 was associated with 
BD patients who had less severe complications including uveitis, thrombosis, and 
neurological and intestinal involvement [47].
3. Interleukin (IL) family genes
3.1 IL-10
IL-10 is a cytokine with anti-inflammatory properties, which plays critical roles 
in modulating immune response and preventing inflammatory and autoimmune 
pathologies [48, 49]. The SNP rs1800871 of the IL10 promoter region was first 
found in an association with BD in the UK and Middle Eastern (ME) cohorts [50]. 
The genome-wide association studies (GWAS) revealed multiple BD-associated 
SNPs (rs1518111, rs1554286, rs1800871, and rs1800872) of the IL-10 in Chinese, 
Turkey, Japanese, and Korean cohorts [51–53].
3.2 IL-12A, IL-23R, and IL-12RB2
IL-12A is a gene which encodes for IL-35 that is a subunit of the heterodimeric 
cytokines IL-12 (encoded by IL-12B) and IL-35. IL-35 binds to a heterodimeric 
IL-12 receptor (IL-12R) that consists of IL-12Rβ1 (encoded by IL-12RB1) and 
IL-12Rβ2 (encoded by IL-12RB2) [54], and it impacts on activation of NK cells and 
polarization of the Th1 pathway through differentiation from naïve CD4+ T cells 
[55, 56]. The association of the IL-12A variants rs1780546 and rs17810458 with BD 
was found in the Turkish and European cohorts [36, 57].
IL-23 is a member of the IL-12 cytokine family. It plays crucial roles in the 
development process of the Th17 cells [58]. The receptor for IL-23 is composed of 
two subunits encoded by the IL-23R and the IL-12RB1 genes [59], and it plays a key 
role in neutrophil inflammation and in autoimmune diseases [60].
A significant association (reaching a GWAS p value) of the IL-23R gene with 
BD was found at the SNP rs11209026 (Gly149Arg) in Japanese, and at the SNP 
rs76418789 (Arg381Gln) in Turkish cohort [61]. The association between BD and 
the IL-23R/IL-12RB2 genes appeared to be consistent in multiple reports with 
different populations including Turkey [52], Japanese [53], Han Chinese [62, 63], 
Iranian [64], Western Algeria [65], and Korean [66].
3.3 IL-33
IL-33 is a member of the IL-1 family that drives production of Th2-associated 
cytokines [67]. A small Iranian cohort of BD patients showed a significantly higher 
prevalence of the IL-33 SNP rs1342326 T/G, and this genotype was also associated 
with higher IL-33 expression in the PBMC of the BD patients [68].
4. Genes involved in inflammation and autoimmunity
4.1 MEFV
The Mediterranean fever (MEFV) protein, also named pyrin is an important 
regulator of innate immunity [69]. Of noting, familial Mediterranean fever 
and BD share inflammatory nature and high prevalence in Middle Eastern and 
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Mediterranean populations. Genetically, the MEFV SNPs rs61752717 Met694Val, 
rs28940580 Met680Ile, and rs3743930 Glu148Gln confer risk to both diseases  
[61, 70–74]. Moreover, Met694Val and Met680Ile of the MEFV gene were also 
associated with greater responsiveness to bacterial products [72, 73].
4.2 IRF8
Interferon regulatory factor (IRF) 8 is a member of the interferon (IFN) 
regulatory factor (IRF) family, and it acts as a transcription factor to regulate the 
development and function of a variety of immune cells. In particular, it regulates 
expression of type I IFN stimulated genes [75], and interacts with the Th17 master 
transcription factor, ROR-γt to inhibit Th17 cell differentiation [76]. In a study with 
Chinese cohort, the IRF8 SNPs rs17445836 and rs11642873 were associated with BD, 
and they appeared to regulate IRF8 expression and corresponding cytokine produc-
tion [77]. In another study with multiple cohorts including Turkish, Iranian, and 
Japanese patients, three other BD-associated SNPs (rs11117433, rs142105922 and 
rs7203487) of the IRF8 gene were reported [78].
4.3 TNFAIP3
TNF-α-induced protein 3 (TNFAIP3) is a ubiquitin-modifying enzyme A20 that 
regulates inflammation through NF-κB signaling pathway, and it can be induced by 
TNF, Toll-like receptors (TLRs), IL-1R, and NOD2 signaling [79–82]. The reports 
of genetic association between TNFAIP3 and BD appeared conflict in studies of 
Chinese and European populations. In the former, the TNFAIP3 SNPs (rs9494885, 
rs10499194 and rs7753873) were associated with BD [83], but were not replicated in 
the latter [84]. On the other hand, a Japanese study of familial BD indicated that a 
missense mutation C243Y in A20/TNFAIP3 was likely responsible for an increased 
production of some inflammatory cytokines by reduced suppression of NF-κB 
activation [85].
4.4 REL
The REL gene encodes for c-Rel, a member of the NF-κB family of transcrip-
tion factors. It may play important roles in regulation of immune activity [86, 87]. 
A Chinese study indicated that the REL SNPs rs842647 may confer susceptibility 
to BD, and the allele C of this SNP was also associated with skin lesions in BD 
patients [88].
4.5 TLR2 and TLR4
Toll-like receptors (TLR) are transmembrane proteins that mediate innate 
immunity by recognizing pathogen molecules [89]. TLR2 and TLR4 are two 
members of the TLR, and they may transduce response to different types of 
pathogens (e.g., in macrophages, the former mainly for Gram-positive bacteria 
and the latter for Gram-negative). The TLR2 SNP rs2289318 (C allele and geno-
type CC) and rs3804099 (CT genotype) were associated with ocular BD in a 
Chinese cohort [90]. The associations of the TLR4 gene with BD are conflict in 
different reports. It was found in Japanese [91], Korea [92] and Turkish cohorts 
[66], but not in Italian [93], Tunisian [94], and Chinese cohorts [95]. Of note, 
two BD protective TLR4 variants identified in the Turkish cohort, p.Asp299Gly 
(rs4986790) and p.Thr399Ile (rs4986791) were associated with hyporesponsive-
ness to endotoxin [96].
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4.6 NOD1 and NOD2
Nucleotide-binding oligomerization domain (NOD)-like receptors are intracel-
lular proteins that regulate innate immune response. NOD1 and NOD2 proteins 
are two members of the NOD family, and they play important roles in initiating 
inflammation in response to microbial components [97, 98]. In a Chinese report, the 
minor allele (G) of the NOD1 SNP rs2075818 was protective from BD [35]. Multiple 
studies indicated that a Crohn’s disease-associated polymorphism, Arg702Trp of the 
NOD2 rs2066844 was also protective from BD [61, 99, 100].
4.7 CCR1 and CCR3
CCR1 and CCR3 proteins are two C-C motif chemokine receptor (CCR) family 
members. They mediate signal transduction within cells in response to pathogens, 
and they are critical for the recruitment of effector immune cells to the site of 
inflammation, and for maintaining homeostasis of the immune system [101]. The 
CCR1 and 3 genes are clustered together on chromosome 3p. The Several SNPs at 
CCR1-CCR3 locus were associated with BD including rs7616215 in Turkish [40] 
and rs13084057, rs13092160 and rs13075270 in Chinese Cohorts [102]. In addition, 
the CCR1 gene was individually associated with BD in multiple cohorts including 
Turkish, Japanese, and Iranian cohorts [36, 103]. Functional studies indicated that 
CCR1 gene expression in primary human monocytes carrying the BD-risk allele was 
reduced along with a weaker activity of monocyte chemotaxis [36].
4.8 GIMAP
GTPase of the immunity-associated protein (GIMAP) family is a group of 
newly identified proteins. Although their functions are still poorly characterized, 
it is believed that they are lymphocyte signaling molecules, and they are also 
involved in survival and apoptosis of T cells and some other cell types [104, 105]. 
A GIMAP cluster including SNPs in GIMAP1 (rs2286900), GIMAP2 (rs10266069 
and rs10256482), and GIMAP4 (rs1916012, rs1522596, and rs1608157) was associ-
ated with BD in a study of Korean and Japanese populations [106], but it failed in a 
replication study of European cohort [107].
4.9 KLRC4
Killer cell lectin-like receptor subfamily C, member 4 (KLRC4) is a member of 
NKG2 receptor family that regulates NK cell function. The association of the KLRC4 
gene and BD was first suggested in the GWAS of Turkish and Japanese cohorts [36], 
and then replicated in the independent study of an Iranian cohort [103].
5. Genes involved in transcriptional activation of immune regulation
5.1 STAT4
Signal transducer and activator of transcription-4 (STAT4) is a transcription fac-
tor that activates gene expression involved in functional regulation and differentia-
tion of T-helper cells, natural killer (NK) cells, mast cells, and dendritic cells [108]. It 
modulates differentiation of naïve T cells into Th1 and Th17 cells [56, 109, 110].
The association between the STAT4 gene and BD appeared to be consistent in 
multiple independent studies including Han Chinese [107], Korean, Turkish, and 
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Iranians [36, 103]. Functional studies indicated that the risk allele A of the STAT4 
SNP rs897200 was correlated with the increased mRNA level of the STAT4 gene, 
and with the increased gene and protein expression of IL-17, as well as with BD 
patients who have a higher clinical severity score [111].
5.2 NCOA5
Nuclear receptor coactivator-5 (NCOA5) protein regulates nuclear receptor 
subfamily 1 group D member 2 (NR1D2) and estrogen receptor 1 and 2 (ESR1 and 
ESR2) [112, 113]. The NCOA5 gene SNP rs2903908 was associated with BD patients, 
especially those affected with genital ulceration and uveitis in the Finland and the 
Turkish cohorts [114].
5.3 FOXP3
FOXP3 (forkhead box P3), also known as scurfin, is a member of the FOX 
protein family of transcription factors. It regulates the development and function of 
T regulatory (Treg) cells [115, 116]. The FOXP3 SNP rs3761548 was associated with 
BD in the North-Western Iranian population [117]. In addition, a low copy number 
variant (CNV) of the FOXP3 gene was reported to confer risk to female BD patients 
in a Chinese cohort [118].
6. Other genes
6.1 PSORS1C1
Psoriasis susceptibility 1 candidate 1 (PSORS1C1) is poorly characterized in 
terms of its biological function. It is initially recognized as a susceptibility locus 
to psoriasis [119] and psoriatic arthritis [120]. Recent studies indicated that it 
is also a shared genetic factor, especially with SNP rs12525170, in other autoim-
mune diseases including systemic sclerosis [121], Crohn’s disease [122], and BD 
[122]. Therefore, it may play important roles in the pathogenesis of autoimmu-
nity [123, 124].
6.2 FUT2
Fucosyltransferase 2 (FUT2) is involved in synthesis of the H antigen, the 
precursor of the ABO-histo-blood group antigen in body fluids, and on the intes-
tinal mucosa [125]. The association between the FUT2 gene (rs632111, rs601338, 
rs602662, rs492602, rs681343, and rs281377) and BD was reported in Iranian and 
Turkish populations [126].
6.3 UBAC2
Ubiquitin-associated domain containing 2 (UBAC2) is another poorly char-
acterized protein, but its gene variants are strongly associated with BD. Limited 
studies suggest that it may function in protein localization in the endoplasmic 
reticulum [127]. The association of the UBAC2 gene with BD was found in 
Turkish, Chinese, Italian, and Japanese populations [128–131]. Functionally, the 
presence of BD-risk rs9517723 allele was correlated with an increased expression 
of the UBAC2 gene.
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6.4 SUMO4
Small ubiquitin-like modifier 4 (SUMO4) is a member of the SUMO family that 
post-transcriptionally sumoylates the targeted proteins to regulate their subcel-
lular localization and/or enhance their stability and activity [132]. It is involved 
in immune regulation by negatively controlling NFκB activity [133]. The genetic 
association between the SUMO4 (SNPs rs237024, rs237026) and BD was first 
reported in a Chinese cohort, and that appeared independent from HLA-B51 [134]. 
The association was replicated in Tunisian and Korean cohorts [135, 136], in which 
specific polymorphisms were also associated with disease severity, skin lesions, and 
vascular involvement of BD patients [135, 136].
6.5 LACC1
LACC1 encodes an oxidoreductase that promotes fatty-acid oxidation. It also 
functions in activation of inflammasome, bactericidal activity of macrophages, 
and production of mitochondrial and NADPH-oxidase-dependent reactive oxygen 
species [137]. SNP rs9316059 of the LACC1 was associated with BD in Turkish, 
Japanese, and Chinese cohorts [78, 138].
6.6 Loci at ADO-EGR2 and CEBPB-PTPN1
Two genetic loci between the ADO and the EGR2 genes and the CEBPB and the 
PTPN1 genes were associated with BD in the Turkish, Iranian, and Japanese cohorts 
[78]. The ADO encodes cysteamine (2-aminoethanethiol) dioxygenase that is 
involved in amino acid metabolism [139]. The EGR2 encodes early growth response 
protein 2 that is a transcription factor, and highly expressed in a population of 
migrating neural crest cells [140]. CEBPB encodes CCAAT/enhancer binding protein 
beta, a member of the CCAAT/enhancer binding protein family of basic leucine 
zipper transcription factors. It functions in controlling cell differentiation, prolifera-
tion, and inflammation [141]. The PTPN1 gene encodes protein tyrosine phospha-
tase, nonreceptor type 1 that functions as a key regulator of immune homeostasis by 
inhibiting T-cell receptor signaling and by selectively promoting type I interferon 
responses after activation of myeloid-cell pattern-recognition receptors [142].
It is worth noting that these BD-linked loci do not directly reflect the association 
of the corresponding genes, but may be suggestive for further investigation of these 
genes in terms of their genetic and functional importance to BD.
7. Conclusion
Multiple genes have been associated with BD, and many of them are involved 
in immune activation and regulation that may suggest their potential biological 
relevance to chronic inflammatory nature of BD. However, exact pathogenic mecha-
nisms of BD on these genes are still unclear. Like many other immune-regulatory 
diseases, this multigenic feature of BD underlies complex pathogenesis. Some of the 
reported associations, for example, TNFAIP3 and TLR4, appeared to be conflict in 
different study cohorts and/or populations, which suggests that the BD-associated 
polymorphisms of the genes may be ethnic specific, or sample selection bias may 
have occurred and further verification may be warranted. In addition, some of 
the BD-associated genes, for example, HLA-B, ERAP1, MICA, and IL family, have 
also been reported in other immune-mediated diseases, which supports the shared 
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genetic effects among these diseases. Moreover, specific gene polymorphisms were 
associated with clinical presentation of BD, for example, HLA-A02:07 with skin 
lesions and arthritis, HLA-A*26:01 with uveitis, HLA-A*30:04 with vascular lesions 
and genital ulcers, MICA-A5.1 with ocular lesions, and MICA-A9 with neurological 
and intestinal involvement. Thus, these specific genotypes may be further explored 
as potential biomarkers for diagnostic or prognostic classification of BD patients.
While the genetic studies have supported multigenic contribution to sus-
ceptibility to BD, epigenetic alternations including DNA methylation, histone 
modifications, and microRNAs regulation have also been reported in BD [143]. 
Furthermore, there is appealing evidence indicating environmental factors, espe-
cially that microorganisms may trigger the disease [144]. Understanding the genet-
ics of BD in conjunction with epigenetics and environmental triggers of BD will 
provide insights into pathogenesis of the disease and an opportunity to interrogate 
candidate genes in potential diagnostic and therapeutic applications.
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